Deudextromethorphan

Drug Profile

Deudextromethorphan

Alternative Names: AVP-786; CTP-786; d-DM; Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]; Deuterated dextromethorphan plus ultra low dose quinidine; Deuterated DM plus ultra low dose quinidine; Deuterated-dextromethorphan; Deuterated-DM

Latest Information Update: 21 Jun 2017

Price : $50

At a glance

  • Originator Concert Pharmaceuticals
  • Developer Avanir Pharmaceuticals
  • Class Antidepressants; Antipsychotics; Antitussives; Morphinans; Neuroprotectants; Opioid analgesics; Organic deuterium compounds; Small molecules
  • Mechanism of Action Cytochrome P 450 enzyme system inhibitors; KATP channel inhibitors; NMDA receptor antagonists; Norepinephrine plasma membrane transport protein inhibitors; Serotonin plasma membrane transport protein inhibitors; Sigma-1 receptor agonists; Sigma-1 receptor antagonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Agitation
  • Phase II Brain injuries; Major depressive disorder; Neurodegenerative disorders; Schizophrenia
  • Phase I Neuropathic pain
  • Preclinical Psychiatric disorders

Most Recent Events

  • 07 Jun 2017 Phase-II clinical trials in Brain injuries (neurobehavioral disinhibition in traumatic brain injury) in USA (PO)
  • 30 May 2017 Avanir Pharmaceuticals initiates enrolment in a phase II trial in Neurodegenerative disorders (In adults, In the elderly) in USA (PO) (NCT03095066)
  • 31 Mar 2017 Avanir Pharmaceuticals plans a phase II trial for Neurodegenerative disorders (In adults, In the elderly) in USA (PO) (NCT03095066)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top